Drug Search Results

SAGE-421

Alternative Names: sage-421, sage421, sage 421
Latest Update: 2023-08-07
Latest Update Note: News Article

Product Description

SAGE-421 is an oral, NMDA receptor positive allosteric modulator that Sage plans to study for potential use in neurodevelopmental disorders and cognitive recovery and rehabilitation. (Sourced from: https://investor.sagerx.com/news-releases/news-release-details/sage-therapeutics-announces-first-quarter-2021-financial-results)

Mechanisms of Action: NMDA Modulator

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Sage
Company Location: CAMBRIDGE MA 02142
Company CEO: Barry E. Greene
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for SAGE-421

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 0: Mood Disorders

Trial	Phase	Trial Status	Disease	Primary Completion Date	Probability of Success

Recent News Events

Date	Type	Title
08/07/2023	News Article	Sage Therapeutics Announces Second Quarter 2023 Financial Results and Highlights Pipeline and Business Progress
05/02/2023	News Article	Sage Therapeutics Announces First Quarter 2023 Financial Results and Highlights Pipeline and Business Progress
02/16/2023	News Article	Sage Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Highlights Pipeline and Business Progress
11/08/2022	News Article	Sage Therapeutics Announces Third Quarter 2022 Financial Results and Highlights Pipeline and Business Progress

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions